Nursing News

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018

  • EMA’s human medicines committee (CHMP) recommended four medicines for approval, including a medicine for use in countries outside the European Union, at its November 2018 meeting.

London, UK (November 16, 2018) - The CHMP adopted a positive opinion for Fexinidazole Winthrop (fexinidazole), the first oral-only medicine (tablets) for the treatment of human African trypanosomiasis, commonly known as sleeping sickness, due to Trypanosoma brucei gambiense. This is the tenth medicine recommended by EMA under Article 58, a mechanism that allows the CHMP to assess and give opinions on medicines for use outside the European Union. For more information, please see the press release in the grid below.

Brown researchers develop new test to objectively measure pain, test medications

PROVIDENCE, R.I., USA (November 7, 2018) -- If you've ever visited the emergency department with appendicitis, or you're one of the 100 million U.S. adults who suffer from chronic pain, you're familiar with a row of numbered faces, with expressions from smiling to grimacing, used to indicate pain levels.  Despite that tool's widespread use, some researchers say a more empirical approach would better serve both patients and the physicians who provide care.

33.000 people die every year due to infections with antibiotic-resistant bacteria

Solna, Sweden (November 6, 2018) - An ECDC study estimates the burden of five types of infections caused by antibiotic-resistant bacteria of public health concern in the European Union and in the European Economic Area (EU/EEA). The burden of disease is measured in number of cases, attributable deaths and disability-adjusted life years (DALYs). These estimates are based on data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) from 2015.

Your showerhead slime is alive

Boulder, Col., USA (November 1, 2018) - The day after Halloween, something scary may still lurk inside your showerhead. Researchers at CIRES have identified Mycobacterium as the most abundant genus of bacteria growing in the slimy "biofilm" that lines the inside of residential showerheads--and some of those bacteria can cause lung disease.

Drugs' side effects in lungs 'more widespread than thought'

Manchester, UK (October 29, 2018) - A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought. Though the 27 drugs treating a range of conditions including arthritis, cancer and the heart are successful for most patients, doctors, say the team, need to be more aware of the potential risks to their respiratory systems.

Study of 500,000 people clarifies the risks of obesity

Bristol, UK (October 25, 2018) - Elevated body mass index (BMI) - a measure of weight accounting for a person's height - has been shown to be a likely causal contributor to population patterns in mortality, according to a new study led by the University of Bristol using measurements and mortality data from 500,000 people. Specifically, for those in UK Biobank (a study of middle to late aged volunteers), every 5kg/m2 increase in BMI was associated with an increase of 16 per cent in the chance of death and 61 per cent for those related to cardiovascular diseases. The work is published today [Thursday 25 October] in Obesity Editors' Choice.

Houston Methodist scientists create device to deliver immunotherapy without side effects

  • Single direct-to-tumor drug-delivery device offers hope for treating triple-negative breast cancer

HOUSTON-(Oct. 23, 2018) - Houston Methodist scientists have developed a nanodevice to deliver immunotherapy without side effects to treat triple-negative breast cancer. Inserted straight into a tumor, this nanofluidic seed makes it possible to deliver a one-time, sustained-release dose that would eliminate the need for patients to undergo several IV treatments over time.

Nurse-led care significantly more successful in treating gout, trial reveals

Nottingham, UK (October 18, 2018) - The research, led by academics at the University of Nottingham and published in The Lancet, has shown that keeping patients fully informed and involving them in decisions about their care can be more successful in managing gout. And the study, which was funded by the charity Versus Arthritis, highlights the importance of individualised patient education and engagement to treat the condition.

2014 regulations led to modest staffing increases but no reduction in rates of patient mortality or complications

Mass. ICU nurse staffing regulations did not improve patient mortality and complications

BOSTON, MA, USA (September 4, 2018) -In 2014, Massachusetts lawmakers passed a law requiring a 1:1 or 2:1 patient-to-nurse staffing ratio in intensive care units (ICU) in the state, as guided by a tool that accounts for patient acuity and anticipated care intensity. The regulations were intended to ensure patient safety in the state's ICUs, but new research led by physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) and published today in Critical Care Medicine found the staffing regulations were not associated with improved patient outcomes.

Surgical outcomes equivalent whether physician anesthesiologist assisted by nurse anesthetist or AA

CHICAGO, ILL, USA (May 29, 2018) - Patients who undergo inpatient surgery experience no difference in death rates, hospital length of stay or costs between admission or discharge whether their physician anesthesiologist is assisted by a nurse anesthetist or an anesthesiologist assistant, according to a new study published in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA).

New model defines successful nurse practitioner-physician co-management

A theoretical model to alleviate primary care strain

Leawood, KS, USA (May 14, 2018) - Co-management of patients by more than one primary care clinician is among new models of care designed to meet the demand for high quality patient care. A new co-management model lays the groundwork for potential care partnerships between nurse practitioners and physicians.

Effort seeks to increase the number of trained rheumatology nurse practitioners and physician assistants

Due to an aging population and increasing prevalence of rheumatic disease, there are growing demands on clinicians who specialize in rheumatology. To meet these demands, the American College of Rheumatology has developed a formal curriculum for nurse practitioners (NPs) and physician assistants (PAs). The curriculum is described in Arthritis Care & Research.

The development of a formal NP/PA curriculum outline in rheumatology is novel and can serve as a tool when adding NPs/PAs into clinical rheumatology practice. No other medical specialty has yet created an endorsed, standardized training tool that can aid in the preparation of NPs/PAs in a medical specialty.

"The Rheumatology Curriculum Outline is a practical tool that can be utilized in various adult and pediatric practice settings," said lead author Benjamin J. Smith, of Florida State University College of Medicine School of Physician Assistant Practice. "We anticipate that it will be used broadly to positively affect rheumatology workforce challenges."

Wiley, April 19, 2018 (tB).

Overcome key challenges in daily diabetes therapy

Integration of latest technology and Personalised Diabetes Management promotes improved outcomes and more time in range

  • Only 6.5% of people with diabetes in Europe reach their therapy targets1
  • Clinical inertia is a key contributor to this and needs to be overcome2 – in a joint effort of physicians, people with diabetes, healthcare systems and industry
  • Latest study evidence shows that integrating innovative technologies and the structured therapy approach of Personalised Diabetes Management improves therapy outcomes and contributes to a better overall glycemic control3
  • An open ecosystem approach with integrated diabetes management solutions addresses clinical inertia and promotes the achievement of more time in range.

Vienna, Austria (February 14, 2018) - Despite all technological innovations of the past years, still only 6.5% of people living with diabetes in Europe are able to achieve their individual therapy targets. Research shows that this can mainly be attributed to multiple factors described as clinical inertia, which includes patient, physician and system-related factors such as e.g. disease denial, medication issues, depression, poor health literacy, too little time in the doctor’s office or poor communication.4 Experts reckon clinical inertia to contribute to people with diabetes living with suboptimal glycemic control for many years, with dramatic consequences in terms of quality of life, morbidity and mortality. This also has a huge impact on the healthcare system due to the high costs associated with uncontrolled diabetes.5

Obesity seen as self-inflicted

Berlin, Germany (February 2, 2018) - Representative survey in Germany, the UK, and the US: Although experts attribute the worldwide increase in obese people primarily to environmental changes, the general public lays the blame on individuals. In their opinion, those suffering from obesity should pay for any resulting medical expenses themselves. This is shown in a current study by the Max Planck Institute for Human Development and the University of Mannheim, published in Annals of Behavioral Medicine.

Late-Breaking Data Presented at IHC Highlight Primary and Secondary Outcome Measure Results from Chronic and Episodic Migraine Phase III Clinical Trials

Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine

Jerusalem, Israel (September 9, 2017) – Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) has presented new data evaluating fremanezumab, an investigational treatment for the prevention of migraine, at the 18th Congress of the International Headache Society (IHC) in Vancouver, Canada. Data presented across two platform presentations and five late-breaking abstracts featured detailed positive efficacy results from pivotal Phase III HALO studies of fremanezumab in chronic (CM) and episodic migraine (EM), as well as data from patient-reported outcomes tools in the chronic migraine trial.

More than 35 presentations and sessions showcase Shire’s gene therapy pipeline and leading factor portfolio: Shire to present new data at ISTH 2017 to advance the standard of care in haemophilia

Zug, Switzerland (June 23, 2017) – Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotechnology company focused on serving individuals with rare diseases, will present research covering a broad range of rare bleeding disorders at the 26th Biennial International Society on Thrombosis and Haemostasis Congress (ISTH), July 8-13, 2017 in Berlin, Germany. Showcased in eight oral presentations, 29 poster presentations and three symposia, these data underscore Shire’s pursuit of treatment innovation rooted in safety, efficacy, and individualized care for hemophilia patients.


Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016

  • Seven medicines recommended for authorisation, 81 overall in 2016

London, GB (December 16, 2016) - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended seven new medicines for marketing authorisation at its December 2016 meeting. This brings the total number of medicines recommended for approval by the CHMP in 2016 to 811.

Nine medicines recommended for approval, including three biosimilars

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016

London, GB (November 11, 2016) - The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval at its November meeting. The CHMP recommended granting a marketing authorisation for Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with haemophilia A.

Toward a hand-held 'breathalyzer' for diagnosing diabetes

Washington, DC, USA (November 9, 2016) - For several years, scientists have been working toward "breathalyzers" that can diagnose various diseases without painful pinpricks, needles or other unpleasant methods. Now, one team has developed a new, portable breath analyzer that could someday help doctors diagnose diabetes noninvasively in the office. The report appears in the ACS journal Analytical Chemistry.

WHO recommends 29 ways to stop surgical infections and avoid superbugs

Geneva, Switzerland November 3, 2016) - People preparing for surgery should always have a bath or shower but not be shaved, and antibiotics should only be used to prevent infections before and during surgery, not afterwards, according to new guidelines from WHO that aim to save lives, cut costs and arrest the spread of superbugs.

New Guideline on Management of Older Patients with CKD

(November 2, 2016) - In the industrialized world, the average age of dialysis patients is constantly rising. People have now a significantly higher life expectancy than 50 years ago, and chronic kidney disease (CKD) is a disease that often occurs in older age. The CKD and dialysis populations are aging, thus posing new challenges for nephrology. Older patients have more comorbidities, a different physiology and, of course, a shorter life expectancy. The latter aspect, especially, may impact therapeutic decisions, for example whether renal replacement therapy should be initiated or conservative treatment be maintained.

Hospital readmission history a valid measure of skilled nursing quality

PROVIDENCE, R.I., USA (November 1, 2016) --When an elderly loved one is discharged from a hospital to a skilled nursing facility (SNF), the family's hope is that they will get good care that will allow them to return home rather than poor care that requires a return trip to the hospital. That's why on its Nursing Home Compare website, the federal government recently included an SNF's historical track record of 30-day hospital readmissions in its ratings of care quality.

Pic.: The aim of OPTIMISTIC -- an acronym for Optimizing Patient Transfers, Impacting Medical quality and Improving Symptoms: Transforming Institutional Care -- is to improve care and communication within nursing facilities and between these facilities and acute-care institutions. Credit: Indiana University Center for Aging Research OPTIMISTIC study

Advance care planning in nursing homes challenging but critical

INDIANAPOLIS , Indiana, USA (November 1, 2016) - The goal of advance care planning is to ensure that the health care an individual receives is consistent with his or her values and preferences. New research shows the critical need for advance care planning and highlights the challenges that healthcare institutions -- especially nursing homes -- face in supporting high quality advance care planning.

Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor for the treatment of patients with metastatic non-small cell lung cancer (NSCLC)

Silver Springs, MD, USA (October 25, 2016) - On October 24, 2016, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test.


Thousands of melanoma patients in Europe have no access to new life saving drugs

COPENHAGEN, Denmark (October 7, 2016 ) - Over 5000 patients with metastatic melanoma in Europe are denied access to new, life saving drugs every year, according to a survey presented at the ESMO 2016 Congress in Copenhagen1. Metastatic melanoma is an aggressive and deadly skin cancer. With innovative targeted therapy and immunotherapy, patients can survive for many years. Unfortunately new therapies are expensive so, according to a survey conducted by Dr Lidija Kandolf-Sekulovic, over 5000 patients with metastatic melanoma in Europe have no access to these drugs.

Researchers look at the role of bacteria in incontinence

Weethinking the role of bacteria in incontinence

Lausanne, Switzerland (October 7, 2016) - We all know that feeling of suddenly needing to pee, and the agonizing worry that we might not find a toilet in time or make it that far. Sadly, for many people this is a regular occurrence and wetting themselves uncontrollably is an inevitable consequence. Almost 1 in 5 women over the age of 44 suffer from what is known as Urgency Urinary Incontinence (UUI): experiencing a strong sensation of an urgent need to pee, followed by immediate leakage of a large volume of urine. It can severely adversely affect someone's life, contributing to anxiety, depression and social isolation.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016

  • Eleven medicines recommended for approval, including three medicines for cancer

London, UK (September 16, 2016) - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended eleven medicines for approval at its September meeting. The CHMP recommended granting a conditional marketing authorisation for Lartruvo (olaratumab) for the treatment of adults with advanced soft tissue sarcoma. Lartruvo is to be used in combination with doxorubicin (a chemotherapy medicine) in patients with advanced soft tissue sarcoma for whom surgery or radiotherapy is not suitable, and who have not been previously treated with doxorubicin. Lartruvo was reviewed under EMA’s accelerated assessment mechanism and has an orphan designation. For more information, please see the press release in the grid below.

Accu_Chek Insight CGM app. Photo and Copyright: RocheUnique features and innovative design

Roche Diabetes Care’s new Accu-Chek® Guide wireless blood glucose monitoring system offers smart solutions for easier testing

                                    • Accuracy surpasses the ISO 15197:2013/EN ISO 15197:201510 requirements for blood glucose monitoring systems
                                    • Easy-to-use with an intuitive user interface and improved testing experience
                                    • Connectivity to the Accu-Chek Connect diabetes management system enables online data exchange with healthcare professionals and caregivers

Munich, Germany (September 12, 2016) - On August 31, 2016, Roche Diabetes Care received clearance by the U.S. Food and Drug Administration (FDA) for the new Accu-Chek Guide blood glucose monitoring system that has been designed to address previously unmet needs of patients and their healthcare professionals. The Accu-Chek Guide system offers a combination of unique features and an innovative design which make it easy and safe to use.

Innovation for relief

Roche Diabetes Care presents new solutions to re-define daily diabetes management

  • New Accu-Chek Guide blood glucose (BG) monitoring system offers easy testing experience, advanced accuracy1.2 and wireless connectivity to a mobile app and cloud-based diabetes management system.
  • New Accu-Chek Insight CGM system provides accuracy and reliability especially in the important hypoglycemic range and phases of fast changing glucose values.3
  • Integrated and personalised solutions are key to ease the management of diabetes in everyday routines and achieve improved therapy outcomes.

Munich, Germany (September 12, 2016) - Daily diabetes management can be stressful and cumbersome for people with diabetes. Moreover, despite the technologies currently available to handle the condition every day, over 50% of people with diabetes who have access to care still do not reach their therapy targets4.

Researchers call for an updated pain scale

Care providers underestimate pain during pediatric burn dressing change

Columbus, Ohio, USA (September 1, 2016) - Dressing changes have been identified as one of the major contributors to perceived pain during burn care, and so it is important that pain be assessed accurately. But a new study from the Center for Pediatric Trauma Research at Nationwide Children's Hospital suggests that pediatric burn pain assessment can vary not only based on patient pain intensity, but also nurse clinical experience.

New study finds connection between chronic pain and anxiety disorders

Burlington, Vermont, USA (August 31, 2016) - New research provides insight into a long-observed, but little-understood connection between chronic pain and anxiety and offers a potential target for treatment. The study's findings, published as an Article in Press in Biological Psychiatry, show that increased expression of PACAP - a peptide neurotransmitter the body releases in response to stress - is also increased in response to neuropathic pain and contributes to these symptoms.

Researchers predict onset of Alzheimer's disease with 85 percent accuracy

Major step towards Alzheimer's blood test

Cardiff, UK (August 31, 2016) - A research team, led by Cardiff University, has made a significant step towards the development of a simple blood test to predict the onset of Alzheimer's disease. Funded by the Alzheimer's Society, the group of researchers from Cardiff University, King's College London and the University of Oxford studied blood from 292 individuals with the earliest signs of memory impairment and found a set of biomarkers (indicators of disease) that predicted whether or not a given individual would develop Alzheimer's disease.

Hospitals should prepare simple standardized treatment protocols for early recognition and treatment of sepsis

Simple measures cut sepsis deaths nearly in half

Nord-Trøndelag, Norway (August 31, 2016) - Researchers were able to cut the number of patients who died from sepsis, or infections that spread to the bloodstream, by 40% (from 12.5% to 7.1%) after the introduction of relatively simple steps at the wards at Levanger Hospital in Nord-Trøndelag, Norway. The steps, which included increased training and a special observation chart, were introduced as part of a research project carried out by Nord University, Levanger Hospital, and the Mid-Norway Centre for Sepsis Research at NTNU and St. Olavs Hospital in Trondheim, Norway.

Digital forms of da ting violence are on the rise - what school nurses need to know

GALVESTON, Texas , USA (August 25, 2016) - Many teens experience physical or sexual abuse within their romantic relationships and now dating violence can also be perpetrated digitally by harassing, stalking or controlling a romantic partner via technology and social media. School nurses are often some of the first to identify such problems and play an active role in preventing them from happening in the first place. They are also in a natural position to act as first responders for victims of an abusive romantic relationship. Information on how school nurses can help these teens experiencing cyber abuse is described in a recent article in NASN School Nurse.

As online and offline forms of dating violence often go together, it is critical that school nurses are able to identify different types of digital dating violence. Digital dating abuse was also found to be associated with online bullying.

"School nurses can prepare for this task by being aware and making others aware that online and offline behaviors are becoming increasingly blurred in teens' lives and that digital dating abuse may be a warning sign of traditional abuse," said Jeff Temple, co-author of the paper and The University of Texas Medical Branch associate professor in the department of obstetrics and gynecology. "Most importantly, school nurses can engage in conversations with students about digital dating abuse, safe Internet use and healthy relationships, letting students know that they can come to them if they encounter online or offline dating violence."

In order to provide credible advice to teens, Temple says that it's important that school nurses are able to speak adolescents' language. They should become familiar and stay connected with advances in technology and popular social media apps.

Cyber dating abuse conversations could focus on what constitutes healthy communication within a romantic relationship and what signals could lead to abuse.

"Potential red flags can be identified, such as sharing pin codes and passwords to phones and apps, excessive contacting or demanding a partner to send a picture of where they are or whom they are with to 'prove' that they are telling the truth," Temple said. "Because of their inexperience with romantic relationships, teens might not know how to appropriately cope with feelings of uncertainty about their relationship and may resort to monitoring as a coping mechanism."

Also, some teens do not always identify abusive behaviors as such, instead considering them to be simply annoying.

Previous investigations have found that 26 percent of surveyed high school students reported being a victim of cyber dating abuse and 12 percent reported having perpetrated cyber dating abuse. Of these students, 9 percent of the teens reported that they were both victim and perpetrator of cyber dating abuse.

In previous studies, Temple also has found that victims of cyber dating abuse are more likely to binge drink, be sexual active, and participate in risky behavior.

Other authors include Joris Van Ouytsel, Michel Walrave and Koen Ponnet from the University of Antwerp, Belgium.

University of Texas Medical Branch at Galveston , 25.08.2016 (tB).

Charité researchers present a new study on the use of stroke emergency mobile ambulance

Is prehospital stroke treatment associated with better outcomes?

Berlin, Germany (August 25, 2016) - When treating a patient with stroke, every minute counts. A specialized stroke ambulance (Stroke Emergency Mobile or STEMO) allows physicians to start specific treatment, such as thrombolysis, at scene. A recent study conducted by researchers from Charité - Universitätsmedizin Berlin investigated whether this earlier response time leads to an improved prognosis. Patients who received the appropriate treatment during transfer to the hospital were less likely to have a disability three months after their stroke than patients who received conventional treatment. Although the difference in surviving without any disability slightly failed to reach the predefined level of significance, other outcomes such as severe disability or death were also more favorable in the STEMO group. Results from this study have been published in the journal The Lancet Neurology*.

Delirium in older patients after surgery may lead to long-term cognitive decline

BOSTON, USA ( July 14, 2016 ) -- Researchers from the Harvard Medical School - affiliated Hebrew SeniorLife Institute for Aging Research (IFAR) have found increasing evidence that delirium in older surgical patients may be associated with long-term cognitive decline. Findings from the study were published today in the July 2016 issue of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Forty years of the Nurses' Health Study

An evidence goldmine with a long-lasting legacy

Ultimo NSW, Australia (July 14, 2016) - It started in 1976 as an investigation into the potential health consequences of oral contraceptives, but the long-running Nurses' Health Study has yielded increasingly greater benefits to scientific knowledge of health and disease, according to a paper published today in the journal Public Health Research & Practice .

Pasta is not fattening, quite the opposite

Pozzilli, Italy (July 5, 2016) - A research from I.R.C.C.S. Neuromed in Pozzilli, Italy, shows that, unlike popular beliefs, pasta consumption does not contribute to obesity; on the contrary: it is associated with a decrease in body mass index. In recent years pasta gained a bad reputation: it will fatten you. This led lots of people to limit its consumption, often as part of some aggressive "do it yourself" diets. Now a study conducted by the Department of Epidemiology, I.R.C.C.S. Neuromed in Pozzilli, Italy, does justice to this fundamental element of the Mediterranean diet, showing how pasta consumption is actually associated with a reduced likelihood of both general and abdominal obesity.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2016

  • Six new medicines, including one cell-based therapy, recommended for approval

London, UK (June 24, 2016) -The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended six new medicines, including one advanced therapy medicinal product (ATMP), for approval at its June meeting. The CHMP recommended granting a conditional marketing authorisation for the ATMP Zalmoxis as an adjunctive, or add-on, treatment for adult patients receiving a haploidentical haematopoietic stem cell transplant (HSCT) for types of blood cancer to aid immune reconstitution and reduce the risk of graft-versus-host disease. Zalmoxis has an orphan designation.

Seeing is believing

Visual triggers increase hand hygiene compliance

Charlotte, N.C., USA ( June 9, 2016 ) - Can you use the "ick factor" to get healthcare workers to clean their hands more often? Yes, according to a new study being presented on June 11 at the 43rd Annual Conference of the Association for Professionals in Infection Control and Epidemiology (APIC) .

FDA approves new drug to treat multiple sclerosis

Silver Spring, MD, USA (May 31, 2016) - The U.S. Food and Drug Administration approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly.